Eli Lilly Has More Than an Ozempic Competitor -- Much More

Over the last year, Eli Lilly's (LLY -3.38%) stock is up nearly 120%. This monstrous move has helped propel the pharmaceutical leader to become the largest health care company in the world by market cap. Although Lilly has a number of medications in its portfolio, perhaps its most popular at the moment is Mounjaro. Mounjaro is a glucagon-like peptide-1 (GLP-1) treatment for diabetes patients. It is also the primary competing product to the incredibly popular Ozempic, which was developed by Novo Nordisk.Desp ...